Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results
FREMONT, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020 , as well as business highlights.
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
FREMONT, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
FREMONT, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration (“FDA") Division of Neurology II
View HTML
Toggle Summary Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines
Review of data from the ZOTRIP trial suggest that Qtrypta showed therapeutic gain at 30 minutes consistent with recently published criteria for evaluating early onset of action All Qtrypta patients who were pain free at 30 minutes were still pain free at 2 hours Observation of pain freedom at 30
View HTML
Toggle Summary Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
FREMONT, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting with the U.S. Food and Drug Administration (“FDA") Division of Neurology II (the “Division”)
View HTML
Toggle Summary Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application
FREMONT, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on December 30, 2020 the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA).
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference
FREMONT, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of the Board of Directors granted a stock option to purchase 100,000 shares of Zosano’s common stock to a new
View HTML
Toggle Summary Zosano Pharma Reports Third Quarter 2020 Financial Results
FREMONT, Calif. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020, as well as recent business updates.
View HTML
Toggle Summary Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™
-- FDA feedback consistent with FDA’s preliminary communication in September-- --Company requesting meeting with FDA to discuss next steps required to resubmit the NDA-- FREMONT, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical
View HTML